Company

Synthorx, Inc.

Synthorx, Inc. is a biotechnology company developing therapies based on a proprietary amino acid.

About

Founded in 2014 and based in the United States, Synthorx develops biopharmaceutical therapies built on a proprietary amino acid, aimed at improving treatment outcomes in various diseases. The company is at the Series C stage. It completed an IPO on December 6, 2018, raising USD 131 mn. Its EBITDA was USD -20.65 mn in the most recent year.

3Funding rounds

6Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in